Benchmark raised the firm’s price target on Ligand (LGND) to $220 from $175 and keeps a Buy rating on the shares after the company reported better-than-expected results for Q3 and increased FY25 guidance.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LGND:
- Ligand price target raised to $275 from $250 at Oppenheimer
- Pelthos Therapeutics acquires Xepi Cream from Biofrontera, Ferrer
- Ligand Pharmaceuticals Reports Strong Q3 Results and Raises Guidance
- Ligand price target raised to $231 from $206 at H.C. Wainwright
- Ligand reports Q3 adjusted EPS $3.09, consensus $1.89